Combined breast and gynecologic surgery: Study says not so fast

July 15, 2019

Breast cancer patients and women undergoing cancer-preventive breast surgeries may consider combining these procedures with hysterectomy and/or ovarian removal. However, a University of Colorado Cancer Center study published in Breast Journal argues against this combined approach: Patients undergoing coordinated breast and gynecologic procedures had a significantly longer length of hospital stay, and higher complication, readmission, and reoperation rates compared with patients who underwent single site surgery.

"This is something I talk with patients about on a weekly basis. Patients have the impression, 'I just want to have one surgery and have everything done.' But complication rates are higher with that approach. In patients at high risk of developing breast cancer and ovarian cancer, 2e recommend doing the prophylactic bilateral mastectomy along with breast reconstruction, but then trying to keep gynecologic surgery separate. It's safer and easier to do them separately," says Sarah Tevis, MD, CU Cancer Center investigator and breast surgeon at UCHealth University of Colorado Hospital.

The study used the National Surgery Quality Improvement Program (NSQIP) database to identify 77,030 women who had undergone breast surgery from 2011 to 2015, of whom 124 also had concurrent gynecologic surgery. Interestingly, it was generally younger, healthier women who chose to have combined breast and gynecologic surgeries, "and still their rate of complications was higher," Tevis says.

In addition to a higher rate of complications, choosing combined surgery may lead to treatment delays. First, the need to coordinate three surgeons - breast, reconstructive, and gynecologic - plus the need to schedule a full day in an operating room often leads to pushing back the date of surgery. Second, breast cancer patients are often treated with chemotherapy following surgery, and complications can delay the start of this important chemotherapy, leading to worse outcomes for patients.

"A few times, a patient has a medical problem that makes it better, for example, to only have one anesthesia. But outside these rare cases, we recommend separating breast and reconstructive surgery from gynecologic surgery," Tevis says.

Tevis and colleagues hope the current study shows the baseline level of complications associated with these surgical strategies. Future work will seek to discover features that may predict individual women who fare better and worse with each approach.

University of Colorado Anschutz Medical Campus

Related Chemotherapy Articles from Brightsurf:

Chemotherapy is used to treat less than 25% of people with localized sarcoma
UCLA researchers have found that chemotherapy is not commonly used when treating adults with localized sarcoma, a rare type of cancer of the soft tissues or bone.

Starved cancer cells became more sensitive to chemotherapy
By preventing sugar uptake, researchers succeeded in increasing the cancer cells' sensitivity to chemotherapeutic treatment.

Vitamin D could help mitigate chemotherapy side effects
New findings by University of South Australia researchers reveal that Vitamin D could potentially mitigate chemotherapy-induced gastrointestinal mucositis and provide relief to cancer patients.

Less chemotherapy may have more benefit in rectal cancer
GI Cancers Symposium: Colorado study of 48 patients with locally advanced rectal cancer receiving neoadjuvant chemotherapy, found that patients receiving lower-than-recommended doses in fact saw their tumors shrink more than patients receiving the full dose.

Male fertility after chemotherapy: New questions raised
Professor Delb├Ęs, who specializes in reproductive toxicology, conducted a pilot study in collaboration with oncologists and fertility specialists from the McGill University Health Centre (MUHC) on a cohort of 13 patients, all survivors of pediatric leukemia and lymphoma.

'Combo' nanoplatforms for chemotherapy
In a paper to be published in the forthcoming issue in NANO, researchers from Harbin Institute of Technology, China have systematically discussed the recent progresses, current challenges and future perspectives of smart graphene-based nanoplatforms for synergistic tumor therapy and bio-imaging.

Nanotechnology improves chemotherapy delivery
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.

Novel anti-cancer nanomedicine for efficient chemotherapy
Researchers have developed a new anti-cancer nanomedicine for targeted cancer chemotherapy.

Ending needless chemotherapy for breast cancer
A diagnostic test developed at The University of Queensland might soon determine if a breast cancer patient requires chemotherapy or would receive no benefit from this gruelling treatment.

A homing beacon for chemotherapy drugs
Killing tumor cells while sparing their normal counterparts is a central challenge of cancer chemotherapy.

Read More: Chemotherapy News and Chemotherapy Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to